Hexagon Capital Partners’s Charles River Laboratories CRL Stock Holding History

Hexagon Capital Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-159	Closed	-$29.4K	–	1852
2024 Q4	$29.4K	Buy	+159	New	+$30.6K	0.01%	651
2024 Q2	–	Sell	-4	Closed	-$1.08K	–	1473
2024 Q1	$1.08K	Sell	4 -8	-67%	-$1.91K	﹤0.01%	1264
2023 Q4	$2.84K	Hold	12	–	–	﹤0.01%	1072
2023 Q3	$2.35K	Hold	12	–	–	﹤0.01%	1040
2023 Q2	$2.52K	Hold	12	–	–	﹤0.01%	1035
2023 Q1	$2.42K	Sell	12 -19	-61%	-$4.31K	﹤0.01%	1033
2022 Q4	$6.75K	Hold	31	–	–	﹤0.01%	834
2022 Q3	$6K	Buy	31 +6	+24%	+$1.29K	﹤0.01%	885
2022 Q2	$5K	Hold	25	–	–	﹤0.01%	791
2022 Q1	$7K	Hold	25	–	–	﹤0.01%	659
2021 Q4	$9K	Hold	25	–	–	﹤0.01%	611
2021 Q3	$10K	Hold	25	–	–	﹤0.01%	589
2021 Q2	$9K	Sell	25 -15	-38%	-$5.01K	﹤0.01%	572
2021 Q1	$11K	Sell	40 -6	-13%	-$1.67K	﹤0.01%	511
2020 Q4	$11K	Hold	46	–	–	﹤0.01%	471
2020 Q3	$10K	Buy	+46	New	+$9.55K	﹤0.01%	451

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Hexagon Capital Partners's CRL Position: Q1 2025 in Review

Hexagon Capital Partners sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 159 shares — an estimated $29.4K sold.

Hexagon Capital Partners first reported a position in CRL in Q3 2020 and held it in 16 quarters. The position peaked at $29.4K in Q4 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

Hexagon Capital Partners reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
Hexagon Capital Partners sold 159 Charles River Laboratories shares in Q1 2025, an estimated $29.4K.
Hexagon Capital Partners first reported a position in Charles River Laboratories in Q3 2020 and held it in 16 quarters.
Hexagon Capital Partners's Charles River Laboratories position peaked at $29.4K in Q4 2024.
561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Hexagon Capital Partners's 13F filing for Q1 2025, filed 29 Apr 2025.